Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) issued its earnings results on Monday. The specialty pharmaceutical company reported $0.01 EPS for the quarter, Zacks reports. The company had revenue of $32.00 million for the quarter. Elite Pharmaceuticals had a negative net margin of 25.70% and a negative return on equity of 6.92%.
Elite Pharmaceuticals Stock Down 0.2%
ELTP stock traded down $0.00 on Thursday, reaching $0.60. The company's stock had a trading volume of 1,506,471 shares, compared to its average volume of 1,241,857. The business has a fifty day simple moving average of $0.56 and a two-hundred day simple moving average of $0.51. Elite Pharmaceuticals has a 12-month low of $0.16 and a 12-month high of $0.82. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.90 and a current ratio of 3.27.
About Elite Pharmaceuticals
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Further Reading
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
